Arash Mostaghimi, MD, MPH, FAAD: Assessing the Safety and Efficacy of Deuruxolitinib in Patients with Alopecia Areata

October 16, 2025

Dr. Mostaghimi reviews pivotal data from the Phase 3 THRIVE-AA1 and THRIVE-AA2 clinical trials, which evaluated the safety and efficacy of deuruxolitinib in patients with alopecia areata. His discussion focuses on how these trial results contribute to the growing body of evidence supporting targeted therapies for autoimmune hair loss.

Topics Covered:

Overview of the THRIVE-AA1 and THRIVE-AA2 trial designs
Key efficacy outcomes in patients with alopecia areata
Safety considerations observed during Phase 3 evaluation
How these findings may influence future treatment strategies

Explore Related Resources:

Use-of JAK Inhibitors for Patients with Alopecia Areata

Treatment Gaps for Patients with Alopecia Areata

MORE EXPERT PERSPECTIVES IN ALOPECIA AREATA:

Ted Lain, MD, MBA: Reviewing Results of the THRIVE-AA1 Trial in Severe Alopecia Areata

Ted Lain, MD, MBA, a board-certified dermatologist at Sanova Dermatology in Austin, Texas, discusses the randomized phase 3 THRIVE-AA1 trial (NCT04518995), which assessed the safety

Amy McMichael, MD: Use of Deuruxolitinib for Hair Regrowth in Patients With Alopecia Areata

Amy McMichael, MD, discusses deuruxolitinib for patients with alopecia areata as an alternative to longer-term treatment options.

Aaron Farberg, MD: Use of JAK Inhibitors for Alopecia Areata Treatment

Dr. Farberg explores the evolving treatment landscape for alopecia areata, with a focus on JAK inhibitors and their role in selectively targeting immune pathways involved

Paradi Mirmirani, MD: Addressing Treatment Gaps for Patients with Alopecia Areata

Dr. Mirmirani examines the current treatment landscape for extensive and severe alopecia areata, focusing on longstanding unmet needs and how recent FDA-approved therapies are beginning

JCAD Archives